(Q53664329)

17 May 2018

title

Antiangiogenic therapy--evolving view based on clinical trial results. (English)

1 reference

17 May 2018

main subject

angiogenesis inhibitor

1 reference

1 reference

17 May 2018

Daniel J. Hicklin

series ordinal

object named as

Daniel J Hicklin

1 reference

17 May 2018

author name string

Lee M Ellis

series ordinal

1 reference

17 May 2018

language of work or name

English

0 references

publication date

14 February 2012

1 reference

17 May 2018

Nature Reviews Clinical Oncology

published in

1 reference

17 May 2018

volume

1 reference

17 May 2018

issue

1 reference

17 May 2018

page(s)

297-303

1 reference

17 May 2018

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Conversion of vascular endothelial cells into multipotent stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Tumor-associated endothelial cells with cytogenetic abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Isolations of a cartilage factor that inhibits tumor neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Analysis of experimental antiangiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

The parallel lives of angiogenesis and immunosuppression: cancer and other tales

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.8

Tumor angiogenesis: therapeutic implications

31 March 2020

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

1 reference

12 December 2020

Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.

1 reference

12 December 2020

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCLINONC.2012.8

1 reference

17 May 2018

1 reference

17 May 2018